MX349878B - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX349878B
MX349878B MX2013001518A MX2013001518A MX349878B MX 349878 B MX349878 B MX 349878B MX 2013001518 A MX2013001518 A MX 2013001518A MX 2013001518 A MX2013001518 A MX 2013001518A MX 349878 B MX349878 B MX 349878B
Authority
MX
Mexico
Prior art keywords
cancer therapy
phenyl
combination anti
pyrrolo
difluoro
Prior art date
Application number
MX2013001518A
Other languages
English (en)
Other versions
MX2013001518A (es
Inventor
Dhingra Kapil
Higgins Brian
Kolinsky Kenneth
E Packman Kathryn
J Lee Richard
Lestini Brian
Su Fei
Original Assignee
F Hoffmann La Roche Ag *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX349878(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche Ag * filed Critical F Hoffmann La Roche Ag *
Publication of MX2013001518A publication Critical patent/MX2013001518A/es
Publication of MX349878B publication Critical patent/MX349878B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una terapia de combinación de {3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]piridín-3-carbonil]-2,4-dif luorofenil}-amida de ácido propán-1-sulfónico o una sal farmacéuticamente aceptable de la misma y un inhibidor de EGFR, para el tratamiento de un paciente que sufre un trastorno proliferativo, en particular un tumor sólido, por ejemplo cáncer colorrectal, melanoma y cáncer de tiroides.
MX2013001518A 2010-08-17 2011-08-16 Terapia de combinacion. MX349878B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37429610P 2010-08-17 2010-08-17
PCT/EP2011/064050 WO2012022724A1 (en) 2010-08-17 2011-08-16 Combination anti - cancer therapy

Publications (2)

Publication Number Publication Date
MX2013001518A MX2013001518A (es) 2013-02-27
MX349878B true MX349878B (es) 2017-08-16

Family

ID=44532840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001518A MX349878B (es) 2010-08-17 2011-08-16 Terapia de combinacion.

Country Status (26)

Country Link
US (1) US8709419B2 (es)
EP (1) EP2605764B1 (es)
JP (1) JP5758003B2 (es)
KR (1) KR101475167B1 (es)
CN (1) CN103153292B (es)
AR (1) AR082691A1 (es)
AU (1) AU2011290818B2 (es)
BR (1) BR112013003530A2 (es)
CA (1) CA2807222A1 (es)
DK (1) DK2605764T3 (es)
ES (1) ES2535000T3 (es)
HR (1) HRP20150648T1 (es)
HU (1) HUE025187T2 (es)
IL (1) IL224395A (es)
MX (1) MX349878B (es)
MY (1) MY161288A (es)
NZ (1) NZ606251A (es)
PL (1) PL2605764T3 (es)
PT (1) PT2605764E (es)
RS (1) RS53959B1 (es)
RU (1) RU2607596C2 (es)
SG (1) SG188207A1 (es)
SI (1) SI2605764T1 (es)
TW (1) TWI530287B (es)
WO (1) WO2012022724A1 (es)
ZA (1) ZA201300967B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TR201816421T4 (tr) * 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
UA114923C2 (uk) 2012-08-17 2017-08-28 Ф. Хоффманн-Ля Рош Аг Комбіноване лікування меланоми, що включає введення кобіметинібу і вемурафенібу
US10179135B2 (en) 2014-01-24 2019-01-15 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2015156674A2 (en) * 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
PT3215158T (pt) 2014-11-07 2019-08-23 Ai Therapeutics Inc Apilimod para utilização no tratamento de cancro renal
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516807A (en) * 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
PT1251850E (pt) 2000-01-26 2006-10-31 Schering Corp Utilizacao de uma preparacao de combinacao na terapia do cancro
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
EP1286671B1 (en) 2000-05-15 2006-04-05 Celgene Corporation Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
MXPA03003161A (es) 2000-10-13 2004-05-05 Vion Pharmaceuticals Inc Formas de profarmaco modificadas de ap/amp.
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US20050176740A1 (en) * 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
AU2004308299B2 (en) 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US20070281041A1 (en) 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
KR100851271B1 (ko) * 2004-06-03 2008-08-08 에프. 호프만-라 로슈 아게 이리노테칸 （ｃｐｔ-１１） 및 ｅｇｆｒ-억제제를 이용한치료
CA2566971A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
CA2604300A1 (en) 2005-04-14 2006-10-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-egfr antibody therapy based on an increased copy number of the egfr gene in tumor tissues
WO2006119395A2 (en) 2005-05-03 2006-11-09 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20060257400A1 (en) 2005-05-13 2006-11-16 Bristol-Myers Squibb Company Combination therapy
TWI522337B (zh) 2005-06-22 2016-02-21 普雷辛肯公司 用於激酶調節的化合物及方法及其適應症
RU2442779C2 (ru) 2005-12-01 2012-02-20 Ф. Хоффманн-Ля Рош Аг Производные 2,4,5-трифенилимидазолина как ингибиторы взаимодействия между белками p53 и mdm2, предназначенные для применения в качестве противораковых средств
WO2007128557A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
KR20090071603A (ko) * 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
TW200901975A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
RU2468819C2 (ru) 2007-08-01 2012-12-10 Идера Фармасьютикалз, Инк. Новые синтетические агонисты tlr9
WO2009099634A2 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
ES2552386T3 (es) 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
US20120035347A1 (en) 2009-04-14 2012-02-09 Schering Corporation Interferon-alfa sensitivity biomarkers
JP5469744B2 (ja) 2009-05-21 2014-04-16 メルク・シャープ・アンド・ドーム・コーポレーション インターフェロンアルファ応答に関連する遺伝子マーカー
RU2553379C2 (ru) 2009-08-24 2015-06-10 Дженентек, Инк. ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
AR082691A1 (es) 2012-12-26
EP2605764A1 (en) 2013-06-26
KR20130043225A (ko) 2013-04-29
PL2605764T3 (pl) 2015-08-31
CN103153292B (zh) 2016-06-29
AU2011290818B2 (en) 2015-08-27
WO2012022724A1 (en) 2012-02-23
PT2605764E (pt) 2015-06-02
US8709419B2 (en) 2014-04-29
HUE025187T2 (en) 2016-07-28
ES2535000T3 (es) 2015-05-04
RU2013110124A (ru) 2014-09-27
EP2605764B1 (en) 2015-03-18
TWI530287B (zh) 2016-04-21
AU2011290818A1 (en) 2013-02-07
CA2807222A1 (en) 2012-02-23
MY161288A (en) 2017-04-14
CN103153292A (zh) 2013-06-12
TW201212915A (en) 2012-04-01
JP5758003B2 (ja) 2015-08-05
IL224395A (en) 2017-09-28
US20120045434A1 (en) 2012-02-23
SI2605764T1 (sl) 2015-06-30
DK2605764T3 (en) 2015-04-07
JP2013537544A (ja) 2013-10-03
MX2013001518A (es) 2013-02-27
ZA201300967B (en) 2015-11-25
HRP20150648T1 (hr) 2015-07-31
RU2607596C2 (ru) 2017-01-10
KR101475167B1 (ko) 2014-12-19
BR112013003530A2 (pt) 2016-06-28
SG188207A1 (en) 2013-04-30
NZ606251A (en) 2015-02-27
RS53959B1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
MY161288A (en) Combination anti - cancer therapy
WO2012022677A3 (en) Combination therapy for the treatment of cancer
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MX2016006119A (es) Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[( 3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer.
MX2013006362A (es) Terapia de combinacion.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MY186099A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
MX2015000428A (es) Composiciones y metodos para regular celulas t car.
NZ628416A (en) Treatment of cancer with tor kinase inhibitors
UA110697C2 (uk) ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
NZ602478A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
NZ628407A (en) Treatment of cancer with tor kinase inhibitors
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
NZ592825A (en) A triazolothiadiazole inhibitor of c-met protein kinase
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
MX2013002155A (es) Compuestos para el tratamiento de cancer.
MX2011012491A (es) Administracion continua de cilengitida en tratamientos contra el cancer.
PH12015501708A1 (en) Methods of treating iron deficiency with soluble ferric pyrophosphate
WO2011159951A3 (en) Targeting tumor associated macrophages using bisphosphonate-loaded particles
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
EP2529225A4 (en) METHOD OF DETERMINING MEANS FOR TARGETING MENA ISOFORMS AND THEIR USE FOR THE DIAGNOSIS AND TREATMENT OF TUMOR METASTASES
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer
MX366911B (es) Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de topoisomerasa i de acción prolongada.

Legal Events

Date Code Title Description
FG Grant or registration